These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3129392

  • 1. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
    Heifetz CL, Bien PA, Cohen MA, Dombrowski ME, Griffin TJ, Malta TE, Sesnie JC, Shapiro MA, Wold SA.
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():29-42. PubMed ID: 3129392
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB, Skulnick M, Marshall PW.
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [Abstract] [Full Text] [Related]

  • 3. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R, Andrews JM, Danks G.
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [Abstract] [Full Text] [Related]

  • 4. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A, Shannon K, Slegg J, Phillips I.
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM, Zemcov SJ, Campbell ME.
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P, de Moor G, Lacroix G, Mambour A, Rossion N, Schuyteneer F.
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [Abstract] [Full Text] [Related]

  • 9. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [Abstract] [Full Text] [Related]

  • 10. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA, Noone P.
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [Abstract] [Full Text] [Related]

  • 11. In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
    Baltch AL, Bassey C, Fanciullo G, Smith RP.
    J Antimicrob Chemother; 1987 Jan; 19(1):45-8. PubMed ID: 3104277
    [Abstract] [Full Text] [Related]

  • 12. [Enoxacin and ciprofloxacin: in vitro effect on Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus].
    Roy C, Foz A, Segura C, Tirado M, Teixell M, Teruel D.
    Med Clin (Barc); 1986 Jan 11; 86(1):1-3. PubMed ID: 2937983
    [No Abstract] [Full Text] [Related]

  • 13. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH, Cowlishaw A, Eley A, Slater G, Greenwood D.
    J Antimicrob Chemother; 1985 Jan 11; 15(1):45-52. PubMed ID: 3156113
    [Abstract] [Full Text] [Related]

  • 14. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM, Baltch AL, Smith RP.
    J Antimicrob Chemother; 1986 May 11; 17(5):623-8. PubMed ID: 2941401
    [Abstract] [Full Text] [Related]

  • 15. In vitro antibacterial activity of enoxacin (CI-919).
    Fernandes CJ, Munro R, Toohey M, Shanker S, Mallon R, Daley D, Harland GS, Stevens DA, Wilson RD, Ackerman VP.
    Pathology; 1986 Apr 11; 18(2):240-2. PubMed ID: 3093961
    [Abstract] [Full Text] [Related]

  • 16. An open study of the safety and efficacy of enoxacin in complicated urinary tract infections.
    Foot M, Williams G, Want S, Roe M, Quaghebeur G, Bates S.
    J Antimicrob Chemother; 1988 Feb 11; 21 Suppl B():97-103. PubMed ID: 3129393
    [Abstract] [Full Text] [Related]

  • 17. The comparative in-vitro activity of pefloxacin.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Apr 11; 17 Suppl B():1-10. PubMed ID: 2940213
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.
    Bassey CM, Baltch AL, Smith RP, Conley PE.
    Antimicrob Agents Chemother; 1984 Sep 11; 26(3):417-8. PubMed ID: 6439116
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX, Neu HC.
    Antimicrob Agents Chemother; 1983 Nov 11; 24(5):754-63. PubMed ID: 6229216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.